Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

Chiara Lazzari; Lorenza Pecciarini; Claudio Doglioni; Federica Pedica; Ana Maria Samanes Gajate; Alessandra Bulotta; Vanesa Gregorc; Maria Giulia Cangi

doi:10.3389/fonc.2022.1038774

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

Front Oncol. 2022 Nov 7:12:1038774. doi: 10.3389/fonc.2022.1038774. eCollection 2022.

Authors

Chiara Lazzari¹, Lorenza Pecciarini², Claudio Doglioni², Federica Pedica², Ana Maria Samanes Gajate³, Alessandra Bulotta⁴, Vanesa Gregorc¹, Maria Giulia Cangi²

Affiliations

¹ Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-IRCCS, Turin, Italy.
² Department of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
³ Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁴ Department of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Abstract

Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors. Larotrectinib and entrectinib have been the first tumor-agnostic compounds approved for the treatment of NTRK fusion-positive tumors. Here, we report the first case of a female patient with a diagnosis of stage IV lung adenocarcinoma harboring the EML4::NTRK3 gene fusion, and successfully treated with entrectinib.

Keywords: EML4::NTRK3 fusion; NGS; NSCLC; NTRK; entrectinib.

Publication types

Case Reports